Chenyu Li
Yaquan Liang
Yuan Qiao- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, Singapore, Singapore
The human gut is the natural habitat for trillions of microorganisms, known as the gut microbiota, which play indispensable roles in maintaining host health. Defining the underlying mechanistic basis of the gut microbiota-host interactions has important implications for treating microbiota-associated diseases. At the fundamental level, the gut microbiota encodes a myriad of microbial enzymes that can modify various dietary precursors and host metabolites and synthesize, de novo, unique microbiota-derived metabolites that traverse from the host gut into the blood circulation. These gut microbiota-derived metabolites serve as key effector molecules to elicit host responses. In this review, we summarize recent studies in the understanding of the major classes of gut microbiota-derived metabolites, including short-chain fatty acids (SCFAs), bile acids (BAs) and peptidoglycan fragments (PGNs) on their regulatory effects on host functions. Elucidation of the structures and biological activities of such gut microbiota-derived metabolites in the host represents an exciting and critical area of research.
Introduction
Over millions of years of evolution, humans have developed a mutualistic relationship with approximately 3.8 × 1013 individual microbes from nearly 1,000 different species in the human intestinal tract, collectively known as the gut microbiota (Ley et al., 2006; Qin et al., 2010; Almeida et al., 2019). At the fundamental level, the human host provides habitats and nutrients to the resident gut microbes, while the microbiota aids in the breakdown of complex carbohydrate fibers that are otherwise indigestible by the host and synthesizes essential vitamins, co-factors, and metabolites for the human body. Thus, the gut microbiota mediates the interactions between indigested food and the host body. The host’s dietary choices and lifestyles can significantly impact the gut microbiota, shaping both the microbial community and the pools of microbiota-derived metabolites (David et al., 2014; Singh et al., 2017; De Angelis et al., 2019; Zmora et al., 2019). While a balanced gut microbiota is critical for maintaining normal host functioning, perturbations to the gut microbiota and their metabolites, known as gut dysbiosis, can have deleterious effects on the host, inflicting a wide range of diseases including inflammatory, metabolic, and neurodegenerative diseases (Cox et al., 2015; Ni et al., 2017; Weiss and Hennet, 2017; Martin et al., 2018).
Remarkably, more than 10% of metabolites in host systemic circulation are of the gut microbiota origin, which act as ligands or hormones that interact with specific host receptors both locally and systemically to modulate downstream effects in the host (Wikoff et al., 2009). In recent years, an increasing number of studies have used untargeted metabolomics to discover novel metabolites of the gut microbiota and focused on deciphering the biological functions of specific metabolites produced by individual gut bacterial strains. In this review, we discuss current knowledge on the roles of gut microbiota-derived metabolites on host health, with a particular focus on three prominent families: short-chain fatty acids (SCFAs), bile acids (BAs), and peptidoglycan fragments (PGNs). Understanding the impact of gut microbiota-derived metabolites on host health is critical for developing potential therapeutic strategies against microbiota-associated diseases.
Short-Chain Fatty Acid
The symbiotic microbes residing in the host gut lumen play the essential function of breaking down dietary carbohydrate fibers indigestible by the host, producing a large amount of short-chain fatty acids, including acetate, propionate, and butyrate as the metabolic end-products. The concentration of SCFAs is estimated to reach 50–100 mM in the colon (Cummings et al., 1987). These small-molecule metabolites are carried by host systemic circulation to reach extraintestinal organs and make broad-range impacts on the host (Silva et al., 2020; Gautier et al., 2021). In particular, SCFAs provide the energy source for colonocytes, mediate host homeostatic response, and participate in gut-brain crosstalk (Vijay and Morris, 2014; Schönfeld and Wojtczak, 2016). As SCFAs are commensal fermentation products, their levels and compositions in the host are influenced by dietary fiber intake as well as consumption of SCFA-enriched foods (Yamamura et al., 2020). Depletions of certain SCFAs can have detrimental effects on the host. Below we summarize the key aspects of SCFAs’ involvement in host health.
SCFAs Regulation of Intestinal Immune Regulation
The host intestinal immune system has co-evolved with the gut microbiota in order to maintain a delicate balance between tolerance to commensal microbes and defense against pathogenic ones (Hooper and Macpherson, 2010). Perturbation of the gut homeostasis can lead to intestinal inflammation and diseases such as inflammatory bowel diseases (IBD; Garrett et al., 2010; Maloy and Powrie, 2011). In the gut, the intestinal epithelial layer serves as the barrier that separates the host from abundant microbes in the luminal contents, while immune cells such as macrophages and T-cells residing in the lamina propria beneath the gut epithelial layer maintain active immunological surveillance (Figure 1; Varol et al., 2010). Abundant microbial SCFAs in the gut lumen modulates the colonic immune system to establish and maintain host intestinal homeostasis. Colonic regulatory T cells (cTreg) play the key role in modulating intestinal homeostasis and suppressing inflammation by reducing the proliferation of effector CD4+ T cells (Teffector; Atarashi et al., 2011; Geuking et al., 2011). SCFAs such as propionic acid and butyric acids, when fed to specific pathogen-free (SPF) mice, can directly increase cTreg forkhead box P3 (Foxp3) and interleukin-10 (Il-10) expression and enhance cTreg differentiation, which offers beneficial adaptive immune responses to the host (Figure 1; Atarashi et al., 2013; Furusawa et al., 2013; Smith et al., 2013). Propionate is recognized by cTreg via G-protein-coupled receptor 43 (GPCR43), encoded by the Ffar2 gene, in a receptor-mediated process to inhibit histone deacetylase (HDAC) activities that control downstream gene expressions (Smith et al., 2013). On the other hand, butyrate is likely to stimulate other GPCRs on myeloid cells to promote Treg cell differentiation (Furusawa et al., 2013). In addition, intronic enhancer conserved noncoding sequence 1 (CNS1)-dependent extrathymic differentiation of Treg cells is also under the regulation of commensal bacteria-derived propionate and butyrate (Arpaia et al., 2013). Recently, SCFAs have also been shown to directly regulate Teffector by promoting microbiota antigen-specific T-helper 1 (Th1) cell Il-10 production (Sun et al., 2018). SCFAs interact with GPR43 and activate signal transducer and activator of transcription 3 (STAT3) and mammalian target of rapamycin (mTOR) pathways in Th1 cells, resulting in the upregulation of transcription factor B lymphocyte-induced maturation protein 1 (Blimp-1) to mediate Il-10 production (Figure 1; Sun et al., 2018). SCFAs-mediated Treg and Teffector cells production of Il-10, the major immunosuppressive cytokines, plays an essential role in maintaining intestinal homeostasis.
Figure 1. Gut microbiota-derived short-chain fatty acids such as acetate, propionate, butyrate regulate host intestinal immune homeostasis, epithelial repair and restoration, and facilitate pathogen clearance in the host gut niche.
Among the different SCFA molecules, butyrate selectively exhibits anti-inflammatory effects on bone marrow-derived macrophages (BMDM) and colonic lamina propria macrophages (Chang et al., 2014). Specifically, butyrate acts as an inhibitor of HDAC in BMDM to affect the expression levels of downstream proinflammatory genes such as Il-6, Nos2, and Il-12b (Figure 1). Although SCFAs are known to be transported into colonic epithelial cells via monocarboxylate transporters MCT1 and MCT4 (Stein et al., 2000; Wang et al., 2006), the uptake mechanism of butyrate into macrophages appears to be different (Chang et al., 2014). Future studies are needed to elucidate the exact pathways of butyrate transportation in macrophages. The ability of microbial butyrate to dampen the proinflammatory response in macrophages effectively prevents overstimulation of the intestinal immune system by commensal bacteria.
Another important factor for maintaining intestinal homeostasis lies in the ability of intestinal epithelial cells (IECs) to replenish and restore the barrier function in the face of inflammatory insult and damage (Peterson and Artis, 2014). Microbial SCFAs play a significant role in promoting IEC restitution. High-fiber diets and acetate treatment in SPF mice showed protective effects on gut epithelial integrity (Macia et al., 2015). Mechanistically, acetate binds to GPR43 and stimulates the K+ efflux in epithelial cells, leading to NLRP3 inflammasome activation and Il-18 production, which are well-recognized pathways for promoting epithelial integrity, repair and homeostasis (Figure 1; Zaki et al., 2010). On the other hand, butyrate mediates epithelial integrity via different pathways. Wang et al. (2020) performed single-cell RNA sequencing in T84 cells treated with a physiological amount of butyrate. The actin-binding protein synaptopodin (SYNPO), a critical intestinal tight junction protein (Mun et al., 2014; Kannan and Tang, 2015), was identified as a top target whose expression is specifically induced by butyrate (Figure 1). The characterization of SYNPO establishes the mechanistic basis of a new aspect of butyrate’s role in maintaining intestinal homeostasis.
SCFAs’ Role in Pathogen Clearance
Short-chain fatty acids offer host protection against enteric pathogens, as the depletion of SCFA-producing commensal bacteria by oral antibiotic treatment increases the likelihood of pathogenic growth in the host gut niche (Rivera-Chávez et al., 2016). On one hand, SCFA molecules can directly exert effects to limit the growth of pathogenic bacteria (Figure 1). For instance, by performing fecal microbiota transplantation from inbred mice that harbor diverse microbiota communities and manifest distinct infection kinetics, Jacobson et al. (2018) identified that abundant Bacteroides spp., such as B. ovatus, B. uniformis and B. acidifaciens, in commensal microbiota offers a high level of colonization resistance against pathogenic S. Typhimurium. Mechanistically, propionate produced by the Bacteroides spp. sufficiently acidifies the cytosolic environment of S. Typhimurium and reduces its lag phase growth, hence limiting the intestinal colonization of S. Typhimurium pathogens. The direct antibacterial effects of propionate are supported by the observations that (1) colonization of a Bacteroides mutant lacking propionate production ability did not offer protection, and (2) inulin-propionate ester treatment in mice, which specifically raises the level of propionate, augmented the colonization resistance (Jacobson et al., 2018). On the other hand, SCFAs can also indirectly enhance the host gut epithelial and immune cell functions for pathogen clearance. Butyrate produced by commensal microbes activates the host epithelial peroxisome proliferator-activated receptor-γ (PPAPγ) signaling pathway, promoting beta-oxidation of the colonic epithelial cells to reduce the oxygen availability in the gut lumen (Figure 1; Byndloss et al., 2017). Depleting butyrate-producing strains results in the increase in nitrate and oxygen levels in the gut, which acts in cooperation with the reduced cTreg population and increased inflammation, favoring the growth of facultative anaerobic Enterobacteriaceae pathogens, including Escherichia coli, S. enterica, and S. Typhimurium (Byndloss et al., 2017). In addition, butyrate also promotes antimicrobial peptides production during macrophage differentiation. During the macrophage colony-stimulating factor (M-CSF)-triggered differentiation of peripheral blood-derived CD14+ monocytes, the presence of butyrate significantly increased the antimicrobial function of macrophages (Figure 1; Schulthess et al., 2019). Metabolomics analysis of butyrate-treated macrophages showed reduced glycolysis, higher adenosine monophosphate (AMP) levels and mTOR inhibition, which are opposite of the pro-inflammatory effects of lipopolysaccharides (LPS). Single-cell RNA sequencing analysis revealed five clusters of butyrate-induced gene expression differences, including lysosomal and antimicrobial signatures via inhibition of the HDAC3 pathway (Schulthess et al., 2019). The effects of butyrate produced by commensal bacteria on macrophages may be involved in preventing intestinal and systemic infections in the host.
SCFAs Involvement in Gut-Brain Crosstalk
Short-chain fatty acids produced by the gut microbiota are involved in gut-brain communication via multiple pathways. The review by Dalile et al. (2019) provided a comprehensive picture of the role of SCFAs in modulating brain function via immune, endocrine, neural, and humoral routes. Recently, Kundu et al. (2019) showed that young germ-free mice manifest increased neurogenesis in the brain after being transplanted with the gut microbiota from aged mice that contained higher proportions of butyrate-producing microbes. Correspondingly, administration of sodium butyrate directly to young germ-free mice results in similar beneficial effects, possibly via the regulation of brain-derived neurotrophic factor (BDNF) expression in hippocampus (Varela et al., 2014; Barichello et al., 2015). In the α-synuclein (αSyn) overexpressing Parkinson’ disease (PD) mice model, however, SCFAs can sufficiently increase neuroinflammation and motor dysfunction (Sampson et al., 2016). Moreover, transplantation of fecal microbiota from Parkinson’s disease patients to the αSyn-expressing mice recapitulates the PD pathophysiology. Thus, identifying specific SCFAs in PD patients may offer key insights into disease aetiology and biomarker discovery.
Bile Acids
Bile acids represent an important class of metabolites in the reciprocal communications between the microbiota and the host. Synthesized from cholesterol in the host liver, primary BAs are stored in the gallbladder and secreted into the duodenum, assisting with the absorption of lipids and fat-soluble vitamins into the host (Joyce and Gahan, 2016). While the majority of the BAs are reabsorbed in the small intestine and recirculated back to the liver, about 5–10% enter the host colon reaching a concentration of 200–1,000 μM (Nguyen et al., 2018), where they undergo quantitative biotransformation by the actions of the gut bacterial enzymes (Ridlon et al., 2006). These microbiota-modified BAs are known as secondary BAs. Apart from their roles in digestion, both primary and secondary BAs are important hormones that interact with host nuclear receptors, including farnesoid X receptor (FXR) and G protein-coupled receptors to influence multiple aspects of host metabolisms, cancer progression, and immunity (Jia et al., 2018; Lavelle and Sokol, 2020; Mohseni et al., 2020; Quinn et al., 2020). Below we focus on recent studies on the roles of microbial bile salt hydrolase (BSH) and functions of specific BA metabolites in host gut homeostasis.
Gut Microbiota BSHs in Secondary BAs Diversification
The host-synthesized bile acids are hydroxylated C24 cyclopentane-phenanthrene sterols conjugated to either glycine or taurine (Russell, 2003). In the gut, the conjugated bile acids encounter the commensal microbes, many of which encode the bile salt hydrolases that hydrolyze the amide bond at the C24 position to yield unconjugated BAs (Ridlon et al., 2006). BSH hydrolysis is a key step that enables further microbial biotransformation including dihydroxylation, oxidation, epimerization of hydroxyl groups, and conjugation/deconjugation of amino acids to introduce structural diversities to secondary BAs (Figure 2A). The importance of microbial BSH activities in BA homeostasis and host metabolism is elegantly demonstrated in several recent studies. Mono-colonization of BSH-expressing E. coli strains into gnotobiotic mice resulted in a significant reduction of total plasma BAs and a specific reduction in tauro-conjugated BAs (Joyce et al., 2014). In addition, it also had a broader impact on host gene expression profiles and physiology, including reduction of weight gain, plasma cholesterol and liver triglycerides. Yao et al. (2018) further identified the BSH from commensal Bacteroides thetaiotaomicron has the selective activity of hydrolyzing tauro-β-muricholic acid. Remarkably, the expression of this single gene and enzymatic activity in the host can alter host metabolisms in both local and systemic levels in mouse models, demonstrating the functional importance of a major BSH from commensal Bacteroides. On the other hand, despite the wide conservation of BSHs in major gut bacterial genera Bacteroidetes and Firmicutes, the microbiota BSH enzymes showcase vastly different substrate specificity (Kawamoto et al., 1989; Yao et al., 2018). In addition to the BSH-expressing bacteria in the host, the bile acid 7-α-dehydroxylating gut bacteria, C. scindens, and C. sordellii, produce secondary BAs that potentiate the effects of endogenous antibiotics in killing pathogenic C. difficile in vitro (Kang et al., 2019). Taken together, understanding the specific functions of individual BSH and other BA-modification enzymes in vivo may identify potential avenues to fine-tune the host’s BA profiles to benefit the host.
Figure 2. Bile acids synthesized in the host liver undergo bile salt hydrolases (BSHs) reaction followed by diverse biotransformation by the gut microbiota to become a variety of secondary bile acid metabolites that play key functions in host homeostasis. (A) The co-metabolism of bile acid in host and gut microbiota. (B) The distinct effects of specific secondary bile acids to T-cell differentiation.
BAs Regulations of Host Innate and Adaptive Immunity
The diverse BAs function as either agnostic or antagonistic ligands of host receptors, influencing both the innate and adaptive immune pathways to modulate host homeostasis. It is well-established that BAs activate FXR receptors to regulate metabolisms. For example, deoxycholate is a specific BA found to promote colon crypt regeneration via activation of FXRs and their downstream innate immune pathways, which is temporally and reciprocally regulated with prostaglandin E2 (PGE2) during the colon wound healing process (Jain et al., 2018). Importantly, ulcerative colitis (UC) patients manifest a reduction of specific secondary BAs, lithocholic acid and deoxycholic acid (Sinha et al., 2020). Administrations of these metabolites at physiologically relevant concentrations afford anti-inflammatory roles in mouse colitis models, likely via immune cells’ TGR5 receptors (Sinha et al., 2020). In addition, BAs have also been shown to inhibit NLPR3 inflammasome via the TGR5-cAMP-PKA pathway to mitigate pathogen infections and inflammations in the host (Guo et al., 2016). Moreover, Ma et al. (2018) revealed that the pools of primary and secondary BAs in the host gut are carried by the portal vein into the liver, affecting hepatic natural killer T (NKT) cell accumulation and liver tumor growth, representing a new aspect of the crosstalk between gut microbiota-mediated BA metabolisms and host innate immunity.
In the context of adaptive immunity, BAs have been shown to regulate T cells functions. Song et al. (2020) established that the gut BA pools from dietary intake and microbial derivatizations affect a distinctive population of RORγ-expressing colonic FOXP3+ cTreg cells, which play essential roles in maintaining colonic homeostasis and the amelioration of colitis severity in the host. Genetic deletions of BSH in the gut symbionts, B. theaiotaomicron and Bacteroides fragilis, reduce their abilities to trigger colonic RORγ+ Treg cell differentiation specifically, without affecting other types of Treg cells in mice. Interestingly, the dominant BA species likely exert their effects by interacting with the BA-sensing nuclear receptor, vitamin D receptor (VDR) that is abundantly expressed in colonic tissues (Song et al., 2020). To determine the specific roles of individual BAs in T cell regulation, Hang et al. (2019) screened a panel of 30 BAs for their effects on Th17- and Treg-cell differentiations from CD4+ T cells and established that 3-OxoLCA inhibits Th17 cell differentiation, while isoalloLCA promotes Treg cell differentiation both in vitro and in vivo (Figure 2B). Mechanistically, 3-OxoLCA directly binds to the retinoid-related orphan receptor-γt (RORγt) transcription factor to inhibit Th17 differentiation, whereas isoalloLCA increases the production of mitochondrial reactive oxygen species (mitoROS) to trigger FOXP3 expression, hence enhancing Treg cell differentiation. Notably, isoalloLCA promotes Treg differentiation via the intronic Foxp3 enhancer, CNS3, which is distinct from the CNS1-dependent pathway mediated by SCFA butyrate (Arpaia et al., 2013). Using RNA-seq and ATAC-seq to interrogate the transcriptomic and genomic changes in isoalloLCA-treated naïve CD4+ T cells, Li et al. (2021) recently identified the NR4A family nuclear receptor, NR4A1, from the NR4A as a nuclear receptor, that is required for the immune-modulatory effects of isoalloLCA on Treg differentiation. Understanding the effects of gut microbiota-derived BAs individually as well as synergistically in modulating host T cell functions are critical for biomarker discovery and therapeutics development for gastrointestinal inflammatory diseases.
Peptidoglycan Fragments
Peptidoglycan is a major component of the bacterial cell wall that serves as a polymeric exoskeleton surrounding the cytoplasmic membrane in bacteria, preventing cell lysis due to the high turgor pressure (Vollmer et al., 2008). Unlike lipopolysaccharide (LPS, also known as endotoxin) which only exists in Gram-negative bacteria, peptidoglycan is an essential structure that is conserved across all bacteria, including Mycobacteria, Gram-positive bacteria and Gram-negative bacteria. The peptidoglycan polymer is made of long glycan strands composed of alternating N-acetyl glucosamine (GlcNAc) and N-acetyl muramic acid (MurNAc) via a β-1,4-linkage, with a short-stem peptide attached to each MurNAc residue. Adjacent stem peptides are further cross-linked to give strength to the peptidoglycan polymer. While the overall peptidoglycan composition is relatively conserved, the identity of the third amino acid of the stem peptide can differ significantly across bacteria (Table 1). Gram-positive bacteria typically possess an L-Lys at the third position of the stem peptide, which is further attached to a specific branch peptide; whereas most Gram-negative bacteria have a unique meso-diaminopimelic acid (mDAP) as the third amino acid in the stem peptide. In addition, some bacteria modify their peptidoglycan glycan backbone, such as 6-O-acetylation of MurNAc, N-deacetylation of GlcNAc and/or MurNAc. Albeit structurally complex, peptidoglycan is not static but undergoes constant remodeling and turnover processes that accommodate cell growth and division (Do et al., 2020; Egan et al., 2020). As a result, bacteria shed soluble peptidoglycan fragments (also known as muropeptides) into the environment during normal growth (Figure 3). Due to their unique presence in bacteria, PGNs are recognized by the mammalian nucleotide-binding oligomerization domain 1 and 2 (NOD1 and NOD2) as pathogen-associated molecular patterns (PAMPs) that activate the host’s innate immune defense in times of bacterial infections (Wolf and Underhill, 2018). The minimal motifs of peptidoglycan that activate NOD1 and NOD2 have been elucidated: the dipeptide, D-γ-Glu-mDAP (iE-DAP) is required for NOD1 activation, and the muramyl dipeptide, MurNAc-L-Ala-D-Glu/Gln (MDP) activates NOD2 (Girardin et al., 2003a,b). However, despite the wide applications of these synthetic ligands, whether the natural PGNs in host exist in the forms of iE-DAP or MDP have not been elucidated. The trillions of commensal bacteria that coexist with the human host likely generate a multitude of PGNs, which have been shown to circulate in human bloodstream ubiquitously (Huang et al., 2019). Recent studies have shed light on the emerging roles of the gut microbiota-derived PGNs as the newest family of microbiota metabolites in maintaining multiple aspects of host health and physiology beyond infections.
Table 1. Summary of bacterial peptidoglycan compositions.
Figure 3. Gut microbiota-derived peptidoglycan fragments (PGNs) in the host gut niche as well as in systemic circulation act to modulate host homeostasis in multiple aspects.
Natural Adjuvants That Calibrate Host Immunity
Bacterial PGNs have long been recognized as vaccine adjuvants to boost host immune responses (Ellouz et al., 1974; Guryanova and Khaitov, 2021). The presence of gut microbiota-derived PGN molecules in healthy individuals raises the exciting prospects of their roles as endogenous adjuvants that calibrate host immunity. However, the existence of bacterial PGN in the human body had remained debatable in the era prior to microbiome research (Sen and Karnovsky, 1984). It was not until recently that Huang et al. (2019) developed a monoclonal antibody 2E7 that specifically recognizes muramyl-dipeptide (MDP), the minimal conserved motif of bacterial peptidoglycan, to enable sensitive ELISA detection of PGNs in host sera. Notably, PGN is undetectable in the serum of germ-free mice, supporting the gut microbiota being the origin of the systemic PGN in the host. The study revealed the ubiquitous presence of microbiota-derived PGNs in all human individuals, while the sera PGN levels significantly increased in patients of the autoimmune diseases rheumatoid arthritis and lupus. Huang et al. (2019) further demonstrated that 2E7-neutralization of the circulatory PGN alleviated arthritis progression in mouse models of the disease, highlighting the potential role of gut microbiota-derived PGNs in autoimmune disease progression. Thus, modulating the levels of microbiota-derived PGNs in the host offers a new prospect for the potential treatment of autoimmune diseases.
Another intriguing study by Griffin et al. (2021) unraveled that small muropeptides, produced by enterococcus peptidoglycan remodeling machinery, could act as natural adjuvants in the host to boost cancer immunotherapy. Commensal bacteria Enterococcus faecium and a few related species encode a secretory protein, antigen-A (Sag A), whose NlpC/p60 domain acts as an endopeptidase that truncates the stem peptide of peptidoglycan, releasing small muropeptides such as MDP and GMDP into the microbiota niche (Figure 3; Rangan et al., 2016; Kim et al., 2019). Administration of these immune-stimulating muropeptides remarkably improved the efficacy of anti-PD-L1 in treating B16-F10 melanoma in the mouse model (Griffin et al., 2021). Probiotic delivery of these immune-active PGN molecules into the host could provide an attractive avenue for tuning these natural immune adjuvants to improve therapeutic efficacies. It will be interesting to investigate if these microbiota-derived PGNs in the host are reliable biomarkers for predicting patients’ clinical response to anti-PD-L1 therapy.
PGNs Regulation of Host Homeostasis
Like other microbiota-derived metabolites, PGNs produced by commensal bacteria play a vital role in maintaining intestinal homeostasis, exerting their impact either through direct effects on gut epithelium or indirect contributions to the host clearance of pathogenic microbes in the gut niche. Using MDP as a model PGN ligand, Nigro et al. (2014) demonstrated that microbiota-derived PGNs promoted the regenerations of the Lgr5+ stem cells in the mouse intestinal crypt via the NOD2-dependent pathway, which offers protective functions to the gut niche, especially under oxidative stress (Figure 3). This study establishes the beneficial role of microbiota-derived PGNs in the direct crosstalk in the intestinal crypt-microbiota interface. In addition, commensal bacteria engage specific PGN molecules to protect the gut niche by enhancing enteric tolerance of pathogenic bacteria. The abovementioned peptidoglycan hydrolase, SagA, produced by the commensal E. faecium, stimulates the mucin and antimicrobial peptide production in gut epithelium via MyD88 and NOD2-mediated innate immune pathways, rendering host gut resistance against S. Typhimurium and Clostridium difficile pathogenesis in the mouse model (Figure 3; Pedicord et al., 2016). The SagA-mediated protective effects on gut homeostasis are likely produced by specific bioactive muropeptides from gut bacteria by the NlpC/p60 hydrolase activity.
Apart from NOD2-dependent protective pathways in the gut, microbiota-derived PGN molecules also prime NOD1 signaling to enhance systemic defenses against pathogen infections. Clarke et al. fed mice with E. coli containing [3H]-DAP-labeled PGNs and detected radioactivity in the mouse serum and bone marrow cells, providing direct evidence for the translocation of DAP-containing PGN fragments from the gut microbiota into the systemic circulation (Weiser et al., 2010). The systemic microbiota-derived PGN molecules significantly facilitated neutrophil clearance of Streptococcus pneumoniae via a NOD1-dependent pathway, as no protective effect was observed in Nod1−/− mice (Figure 3; Weiser et al., 2010). Consistently, administration of NOD1 ligands into germ-free mice can restore the hematopoietic stem cells in the bone marrow and stimulate cytokine productions, supporting that NOD1 signaling participates in the maintenance of steady-state hematopoiesis in the host (Iwamura et al., 2017).
Given that the levels and specific structures of PGNs in the host are important in maintaining host homeostasis, a perturbed level of the microbiota-derived PGNs may have detrimental effects. Oral administration of broad-spectrum β-lactam antibiotics, which inhibit bacterial peptidoglycan biosynthesis, has been shown to induce a sudden significant increase in PGN levels, known as “peptidoglycan storm,” in the gut of mice (Tan et al., 2021). The β-lactam-induced PGN storm profoundly impacts the bacteria-fungal interaction, strongly promoting the invasive hyphal growth and systemic dissemination of pathogenic Candida albicans in mice (Figure 3), hence establishing the underlying mechanistic basis for β-lactam antibiotics-associated fungal infections in the clinic.
PGNs’ Involvement in Metabolic Diseases
Many metabolic diseases, including diabetes, manifest systemic low-grade chronic inflammation characterized by infiltrating immune cells such as macrophages and neutrophils into the metabolic tissues such as the liver, adipose tissues, and skeletal muscles (Fink et al., 2014; Morinaga et al., 2015). In particular, activation of the NOD innate immune pathways is pertinent in the immuno-metabolic interface and insulin resistance. In mice fed with a high-fat diet (HFD), their sera contain higher levels of NOD1-activating ligands, which are likely mDAP-containing PGNs that originated from the gut bacteria or diet (Chan et al., 2017). Administration of NOD1 ligands into mice triggers insulin intolerance without affecting the body weight or adiposity. Specifically, the NOD1 ligand-induced insulin resistance do not involve significant elevation of serum cytokines, which is in contrast to the response of low-dose LPS, the major contributor of metabolic endotoxemia (Schertzer et al., 2011). Hematopoietic deletion of NOD1 offered protective effects against diet-induced glucose and insulin intolerance in mice, which could be partially due to the decreased CXCL1 production by macrophages in the adipose tissue and hence reduced neutrophil migration (Figure 4; Chan et al., 2017). Understanding of neutrophil functions in NOD1-dependent whole-body insulin resistance and metabolic inflammations await further investigations. Consistently, the proinflammatory effects of NOD1 activators have been established in in vitro cell culture assays, where they trigger MAPK- and NF-kB-mediated proinflammatory gene expression such as MCP-1, TNFα, Il-6 in adipose tissues (Zhao et al., 2011). Furthermore, Zhang et al. (2019) recently demonstrated that gut microbiota-derived NOD1-activating PGNs in the host circulatory system could directly modulate insulin trafficking in pancreatic beta cells. Mechanistically, PGN ligand binding to NOD1 in pancreatic beta cells triggers NOD1 and receptor interacting protein-2 (Rip2, also known as RIPK2) localization to insulin vesicles and recruits Ras-related protein Rab-1a for insulin transportation. This provides opportunities to further decipher the identities of these endogenous microbiota-derived NOD1 activators that regulate host glucose tolerance in the gut-islet axis.
Figure 4. Peptidoglycan fragment agonists of NOD1 and NOD2 pathways manifest opposing effects on insulin resistance in high-fat diet mice. While MDP, a NOD2 ligand that triggers overexpression of IRF4 via PIPK2 in non-hematopoietic cells, ameliorates insulin resistance induced by high-fat diet in mice, the iE-DAP agonist of NOD1 pathways induces Cxcl1 expression via RIPK2 in hematopoietic cells that contributes to insulin resistance in high-fat diet mice.
Different from the widespread expression of NOD1 in most cell types, NOD2 is exclusively expressed in a limited number of cells such as intestinal epithelium and immune cells in mammals (Caruso et al., 2014). In parallel with the NOD1-mediated adipocyte and hepatocyte inflammations in insulin resistance, NOD2 activation by the corresponding PGN ligands in skeletal muscle cells also provoked insulin resistance via cell-autonomous innate immune responses (Tamrakar et al., 2010). Administration of MDP to myotube cells in vitro significantly impairs insulin-stimulated glucose uptake and activates proinflammatory cytokine release, suggesting a direct causal relationship between NOD2 activation and insulin resistance in skeletal muscle cells in vitro. However, whether such cell-autonomous proinflammation holds true in mice fed with NOD2 agonists remain to be investigated, since the interpretation of NOD signaling being universally proinflammatory may be an over-simplification of the in vivo effects (Cavallari et al., 2020). Cavallari et al. (2017) recently reported that the intraperitoneal administration of MDP into two different HFD-based obesity mice models surprisingly improved insulin and glucose tolerance without altering other parameters such as body mass, adiposity, serum endotoxin levels as well as gut microbiome composition. Mechanistically, MDP exerts its insulin-sensitizing effects in adipose and hepatic tissues via the activation of NOD2 and hence increased expression of interferon regulatory factor 4 (IRF4), a downstream transcription factor involved in anti-inflammatory response; whereas IRF4 was dispensable for the NOD1-mediated insulin resistance via hematopoietic cells (Cavallari et al., 2017). Interestingly, the common adapter protein Rip2 in both NOD1/2 signaling is involved in the dichotomous metabolic effects in different cell types (Figure 4; Cavallari et al., 2020). As a result, the cell-specific and ligand-specific NOD innate immune responses are complex and require multiple levels of regulations in conferring whole-body metabolic effects (Schertzer and Klip, 2011). For instance, the localization and compartmentalization of specific PGN agonists in various cells and tissues may be important for eliciting precise immune and metabolic responses (Cavallari et al., 2020). The selective uptake of NOD1 or NOD2 agonists by different cells may play a role in the divergent responses. Yet, the host’s transport mechanisms of microbiota-derived PGN molecules are beyond current knowledge (see next section). Moving forward, for developing PGN postbiotic therapeutics, a key challenge is to define how different immune-metabolic pathways respond to diverse arrays of microbiota-metabolites are orchestrated in the host. Addressing the compositions, distributions, and levels of natural gut microbiota-derived PGNs in individuals may offer new perspectives.
PGNs in the Gut-Brain Axis
The presence of commensal microbiota-derived PGN molecules in the host circulatory system (i.e., serum and cerebrospinal fluid) under basal conditions establishes the necessary prerequisite for PGNs to reach and regulate extraintestinal organs such as the brain. Recent studies have shed insights on their involvement in normal brain development and chronic brain inflammations in diseases such as multiple sclerosis (MS) via the regulation of innate immune pathways in the brain (Gonzalez-Santana and Diaz Heijtz, 2020; Laman et al., 2020). Using an enzymatic colorimetric-based silkworm larvae plasma (SLP) assay to detect bacterial PGN, Arentsen et al. (2017) demonstrated that higher PGNs are present in the cerebellum of juvenile SPF mice than germ-free (GF) mice, validating that microbiota-derived PGNs can indeed cross the blood-brain barrier (BBB). Interestingly, the cerebellum PGN levels increased in an age-dependent manner, which parallels the gut microbiota colonization process in mice. Corroboratively, the expression of peptidoglycan-recognition protein 2 (PGRP2) and the putative PGN transporter PepT1 also significantly increases during this specific postnatal period in the developing brain and are sensitive to changes in the gut microbiota. PGRP2-mediated signaling is critical for brain development and behavior in mice, as PGRP2−/− mice manifest altered expressions in synapse-related genes including autism risk gene c-Met and abnormal social behavior (Arentsen et al., 2017). This seminal study demonstrated the emerging role of microbiota-derived PGNs in the gut-brain axis. However, the lack of knowledge in the gut microbiota composition and PGN profiles in host impedes the establishment of direct causal effects. Further studies are needed for elucidation of the specific subtypes of PGN molecules recognized by PGRPs and to address their exact functions in the developing brain.
In chronic brain inflammatory diseases such as multiple sclerosis (MS) with its experimental autoimmune encephalomyelitis (EAE) model, the host blood-brain barrier is severely damaged, indicative of inflammatory activity, which, in principle, facilitates the translocation of systemic PGNs into the brain. Consistently, PGNs were found to be concentrated in lesion regions in postmortem MS patients as well as in live patients (Schrijver et al., 2001; Branton et al., 2016). Purified PGNs can promote EAE development in mice via NOD signaling to engage RIP2 and RICK in infiltrating dendritic cells (DCs), and neutralizing antibodies against circulating PGNs can ameliorate disease progression (Shaw et al., 2011). Notably, pathogenic bacterial infections are also sources of elevated systemic PGNs contributing to host inflammation. In the maternal-fetal interface, bacterial PGNs (and other bacterial cell wall products) from the mother can translocate across the placenta to trigger neural proliferation in the fetal brain and result in abnormal postnatal cognitive behaviors (Humann et al., 2016). These studies suggest the potential pathological functions of commensal and pathogenic bacteria-derived PGNs in brain inflammations. Future prospective studies to profile the gut microbiota composition and the microbiota-derived-PGNs in these patients may uncover valuable PGN biomarkers for brain disease diagnosis.
Host Transporters for PGNs Uptake
As the mammalian innate immune NOD1 and NOD2 sensors reside in the cytosolic space in host cells, the soluble PGNs produced by the gut microbiota must find their ways into the cells for binding to the cognate NOD targets. Bastos et al. (2021) recently published a comprehensive review on the uptake and recognition of PGNs by mammalian hosts, below we highlight known mammalian transporters that may implicate in the transportation of natural microbiota-derived PGNs into host cells. The seminal work by Vavricka et al. (2004) established that the di/tripeptide hPepT1 of the solute carrier 15A1 (SLC15A1) family transports MDP into human colonic epithelial Caco2-BBE cells. Critically, the authors used radiolabeled [3H]-MDP to directly demonstrate the time- and concentration-dependent uptake in hPepT1-expressing cell lines. While hPepT1 is only minimally expressed in the colonic epithelial cells under normal physiological conditions, it is strongly overexpressed in chronic colonic inflammations such as IBD (Vavricka et al., 2004). Interestingly, its expression window in the brain tissues also coincides with the period of gut microbiota colonization in mice (Arentsen et al., 2017). On the other hand, whether hPepT1 also transports other PGNs still remains inconclusive: in the in vitro competition assay using hPepT1-expressing Xenopus laevis oocytes, GMDP and other NOD1-activating PGNs, unlike MDP, failed to inhibit the cellular uptake of a specific hPepT1 substrate, [3H]-Gly-Sar (Ismair et al., 2006), whereas opposite results were observed in a similar competition assay in Caco-BBE cells and lung epithelial cells (Dalmasso et al., 2010; Hu et al., 2018). As a result of the great challenges with obtaining substantial quantities of PGNs for biological assays, direct measurements using radiolabeled PGNs to validate the involvement of hPepT1 in their transportations are not feasible yet (Ismair et al., 2006). Additionally, a distantly related SLC46 family transporter in Drosophila has been suggested to transport tracheal cytotoxin (TCT), a natural PGN released by pathogenic Bordetella pertussis (Paik et al., 2017). Yet whether mammalian SLC46 also participates in PGNs uptake process has not been established in direct assays. Furthermore, fluorescent MDPs are valuable for visualization of the uptake process in host cells. For instance, specific endo-lysosomal transporters, SLC15A3 and SLC15A4, are found to mediate the selective endosomal escape of MDP, facilitating the recruitment of NOD2 sensor and downstream effectors onto endosomal platforms in mammalian dendritic and macrophage cells (Nakamura et al., 2014; Hu et al., 2018). Overall, while current studies indicate that the SLC15 family of transporters play prominent roles in canonical PGN ligands uptake, our understanding of the uptake process is far from clear. It is plausible that PGNs uptake occurs in a subtype-specific and cell-specific and manner, where distinct host cell types engage different mechanisms for diverse PGN subtypes. Hence, efforts to unravel the natural structures of microbiota-derived PGNs in host and to develop facile access to obtain them (and their probes) are urgently needed to facilitate the mechanistic elucidations.
Other Microbiota-Derived Metabolites
Tryptophan and Indole-Derivatives
Tryptophan is an essential amino acid that structurally contains an indole aromatic ring. As human enzymes do not synthesize tryptophan, it can only be obtained from dietary proteins (Roager and Licht, 2018). While the majority of the ingested proteins are absorbed in the small intestine in the host, a considerable amount of tryptophan and tryptophan-containing peptides can reach the colon, where the gut microbiota transform them into a diverse family of indole-derivatives, such as indole, indole-acetic acid (IAA) and indole-propionic acid (IPA; Figure 5; Geypens et al., 1997). The absence of indole-derivatives in germ-free mice indicates the involvement of microbiota in their production (Wikoff et al., 2009). Extensive studies have revealed key functions of microbiota-derived indole derivatives as signaling molecules in host metabolisms (Agus et al., 2018, 2021; Roager and Licht, 2018). In this section, we mainly focus on indole derivatives’ activation of the host’s aryl hydrocarbon receptor (AhR) pathway.
Figure 5. L-tryptophan from dietary proteins is metabolized by gut microbiota into a variety of indole derivatives, which are potent AhR agonists in the host.
Aryl hydrocarbon receptor is a cytosolic transcription factor widely expressed in host immune cells and involved in various innate and adaptive immune responses upon activation by specific endogenous ligands and xenobiotics (Rothhammer and Quintana, 2019). Microbial-derived tryptophan and indole derivatives are agonists for AhR, yet their affinities toward AhR from mice and humans differ substantially (Hubbard et al., 2015). Interestingly, indole metabolites are significantly reduced in fecal samples from individuals with metabolic syndrome and HFD-fed mice. Supplementation of Lactobacillus reuteri, a high producer of indole derivatives, to HFD-fed mice was sufficient to restore AhR-dependent metabolic homeostasis, including insulin sensitivity, intestinal barrier function, and glucagon-like peptide-1 (GLP-1) hormone production (Natividad et al., 2018). In addition, specific indole-derivatives are shown to exhibit anti-inflammatory activities via AhR signaling (Figure 5). For instance, IAA can prevent HFD-induced antibiotics tolerance in mice by acting synergistically with bactericidal antibiotics such as ciprofloxacin, possibly by promoting bacterial metabolism and ROS production (Liu et al., 2021). IPA and indoleacrylic acid (IA) produced by Peptostreptococcus russellii, a mucin-utilizing bacteria, promote goblet cell functions via AhR signaling, hence boosting gut barrier functions and ameliorating inflammatory responses (Wlodarska et al., 2017). Furthermore, the indigenous spore-forming bacteria in the gut microbiota mediate the production of 5-hydroxytryptamine (5-HT), also known as serotonin, by promoting Thp1 tryptophan digestion in host colonic enterochromaffin cells (Yano et al., 2015). Apart from being an important neurotransmitter, serotonin hold key regulatory functions in governing host gut homeostasis. Local accumulation of serotonin in the gut contributes to its systemic translocation and uptake by circulating platelets, promoting host GI motility and global homeostasis (Yano et al., 2015). While most microbiota-derived indole derivatives offer beneficial effects, one notable exception is indoxyl sulfate (IS), which is converted from indoles by cytochrome P450 enzymes in the host liver (Brydges et al., 2021). A uremic toxin, IS accumulates significantly in the sera of chronic kidney disease patients. Excessive IS that activates AhR signaling in endothelial cells impairs angiogenesis, substantially increasing the chance of cardiovascular diseases (Dou et al., 2007; Schroeder et al., 2010; Wu et al., 2011).
Therefore, proper gut microbiota-host crosstalk that regulates both the concentration and diversity of the indole metabolites pool in the host is essential for host health and functioning. Although a wide range of tryptophan and indole ligands can activate AhR signaling, individual metabolites may elicit distinct downstream effects. Elucidation of the biological impact of specific microbiota-derived indole derivatives is necessary for developing therapeutic strategies targeting this pathway.
Trimethylamine N-oxide
Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite first identified in human sera as a risk predictor for cardiovascular diseases in an untargeted metabolomics study in 2011 (Wang et al., 2011). The host gut microbiota plays the essential role in metabolizing dietary phosphatidylcholine, betaine, and L-carnitine precursors into trimethylamine (TMA). As illustrated in Figure 6, key microbial enzymes involved in TMA production include TMA lyase (CutC) and its activating protein (CutD; Craciun and Balskus, 2012), the seleonocysteine-containing betaine reductase (GrdH), and a two-component system composed of an oxygenase (CntA) and an associated reductase (CntB) (Zhu et al., 2014). Subsequently, TMA traverses across the intestinal epithelium into host systemic circulation and is carried to the liver, where the host hepatic flavin monooxygenase (FMO) converts TMA to TMAO (Yang et al., 2019). Circulatory levels of TMAO in individuals are closely associated with cardiovascular diseases (Witkowski et al., 2020). Mechanistically, TMAO promotes atherosclerosis and thrombosis by activating NLRP3 inflammasomes, NF-kB and MAPK signaling in vascular smooth muscle cells and endothelial cells, triggering proinflammatory gene expression and endothelial adhesions (Yang et al., 2019). Since the gut microbiota participates in a vital step in TMAO production in the host, inhibition of specific microbiota enzymes may effectively regulate TMAO levels in the host. Notably, the unique activity of microbial CutC/D enzymes that cleave the C-N bond of choline is absent in the mammalian counterpart, making them attractive targets for inhibition. The natural product, 3,3-dimethylbutanol (DMB) has been shown to be a potent inhibitor of CutC/D, which effectively reduces circulating TMAO and thwarts atherosclerosis in a mouse model (Wang et al., 2015). Certain halomethylcholines can irreversibly inhibit microbial TMA lysate gene via a suicide substrate mechanism (Roberts et al., 2018). Remarkably, a single dose of the inhibitor effectively reduced plasma TMAO in mice for a sustained period without exerting host toxicity (Organ et al., 2020). This study exemplifies the promise of modulating the microbiota-host crosstalk by selectively targeting microbiota enzymes to mitigate host diseases. In addition, dietary interventions with prebiotics, probiotics and other bioactive or phytochemical compounds represent another promising approach to modulate the production of gut microbiota-derived TMAO, hence suppressing the circulating levels of TMAO in host (Simó and García-Cañas, 2020).
Figure 6. The gut microbiota is involved in converting dietary phosphatidylcholine into TMA, which is transported to the host liver and converted to TMAO that is strongly associated with cardiovascular disease in the host.
Polysaccharide A
Polysaccharide A (PSA), which belongs to one of the eight structurally distinct capsular polysaccharides (CPS) in the major commensal and non-enterotoxigenic bacteria B. fragilis, has been shown to exhibit considerable beneficial effects to human health (Ramakrishna et al., 2019; Vernay et al., 2020). PSA is the most well-recognized immunomodulatory zwitterionic carbohydrate molecule from the gut microbiota (Surana and Kasper, 2012). Mono-colonization of GF and SPF mice with either PSA-producing B. fragilis strains or purified PSA molecules affords an increase of CD4+ T lymphocyte populations and corrects Th1/Th2 imbalance in the mice spleen, supporting the role of microbiota zwitterionic PSA as a potent T cell-dependent antigen (Mazmanian et al., 2005). Mechanistically, B. fragilis PSA is recognized by CD11c+ DCs residing in the colonic lamina propria to reach the mesenteric lymph nodes (MLNs) and stimulate T cell responses. This occurs without B. fragilis PSA ever reaching the systemic circulation in the host (Mazmanian et al., 2005). Moreover, Round et al. (2011) discovered that colonization of GF mice with non-PSA-expressing B. fragilis resulted in a significant increase in the proinflammatory Th17 cell responses in the gut, which is absent in mice colonized with wild-type B. fragilis, suggesting that PSA performs an active symbiotic function in suppressing proinflammation and promoting immunologic tolerance in the host. Specifically, PSA signals Foxp3+ through TLR2 in Treg cells to induce anti-inflammatory Il-10 cytokine production in the gut. It is surprising that, unlike other known PAMP ligands that trigger proinflammatory responses via TLR2 signaling, PSA has evolved to promote symbiotic tolerance via TLR2 activation of Treg cells instead. Therefore, defining specific functions of the gut microbiota-derived molecules in the host is of great importance. Furthermore, B. fragilis PSA has been shown to offer protection in the mouse model of colitis via both innate and adaptive immune pathways by triggering the plasmacytoid DCs (PDCs) via TLR2 activation to mediate colonic Treg cells to produce anti-inflammatory IL-10 to dampen intestinal inflammation (Dasgupta et al., 2014). Besides the archetypal B. fragilis PSA of the gut microbiota, Neff et al. (2016) has performed a genome screen to uncover more immunomodulatory zwitterionic polysaccharides (ZPSs) encoded by other commensal bacteria. Such efforts to discover the structures and mechanisms of diverse microbiota-derived ZPSs will open up opportunities for potential therapeutic developments against intestinal inflammations of the host.
Conclusion
Over the eons of evolution, the trillions of microbes residing in the human gut have developed a symbiotic relationship with the host, where the gut microbiota-derived metabolites serve as effector molecules modulating host functioning in the gut niche as well as in the extraintestinal organs. The gut microbiota possesses unique enzymatic capabilities to convert dietary molecules (i.e., dietary fibers and tryptophan-rich proteins) and host metabolites (such as conjugated primary bile acids), and de novo synthesize bacterial carbohydrate molecules (such as PGN fragments and PSA), producing a trove of microbiota-derived metabolites in the host. These microbiota-derived metabolites impact the host by acting as ligands for various receptors to stimulate downstream effects. In summary, characterization of the structures and functions of these microbiota-derived molecules in the host holds the promise to uncover the underlying mechanisms of gut microbiota-host crosstalk, opening up potential avenues for therapeutic interventions to microbiome-associated diseases in humans. We are in an exciting era that novel microbiota-derived metabolites are being uncovered from untargeted metabolomics and genome mining approaches. The challenge is to elucidate the biological roles of these chemical messengers and how they cause or contribute to various human diseases.
Author Contributions
CL and YQ conceptualized the work. CL, YL, and YQ wrote the manuscript and made the figures. All authors contributed to the article and approved the submitted version.
Funding
The work is supported by the Singapore National Research Foundation (NRF) under NRF fellowship award NRF-NRFF12-2020-0006, and a Nanyang Technological University start-up grant (NTU-SUG) to YQ.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Agus, A., Clément, K., and Sokol, H. (2021). Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut 70, 1174–1182. doi: 10.1136/gutjnl-2020-323071
Agus, A., Planchais, J., and Sokol, H. (2018). Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23, 716–724. doi: 10.1016/j.chom.2018.05.003
Almeida, A., Mitchell, A. L., Boland, M., Forster, S. C., Gloor, G. B., Tarkowska, A., et al. (2019). A new genomic blueprint of the human gut microbiota. Nature 568, 499–504. doi: 10.1038/s41586-019-0965-1
Arentsen, T., Qian, Y., Gkotzis, S., Femenia, T., Wang, T., Udekwu, K., et al. (2017). The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior. Mol. Psychiatry 22, 257–266. doi: 10.1038/mp.2016.182
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., Van Der Veeken, J., Deroos, P., et al. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455. doi: 10.1038/nature12726
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., et al. (2013). Treg induction by a rationally selected mixture of clostridia strains from the human microbiota. Nature 500, 232–236. doi: 10.1038/nature12331
Atarashi, K., Umesaki, Y., and Honda, K. (2011). Microbiotal influence on T cell subset development. Semin. Immunol. 23, 146–153. doi: 10.1016/j.smim.2011.01.010
Barichello, T., Generoso, J. S., Simões, L. R., Faller, C. J., Ceretta, R. A., Petronilho, F., et al. (2015). Sodium butyrate prevents memory impairment by re-establishing BDNF and GDNF expression in experimental pneumococcal meningitis. Mol. Neurobiol. 52, 734–740. doi: 10.1007/s12035-014-8914-3
Bastos, P. A. D., Wheeler, R., and Boneca, I. G. (2021). Uptake, recognition and responses to peptidoglycan in the mammalian host. FEMS Microbiol. Rev. 45:fuaa044. doi: 10.1093/femsre/fuaa044
Branton, W. G., Lu, J. Q., Surette, M. G., Holt, R. A., Lind, J., Laman, J. D., et al. (2016). Brain microbiota disruption within inflammatory demyelinating lesions in multiple sclerosis. Sci. Rep. 6:37344. doi: 10.1038/srep37344
Brydges, C. R., Fiehn, O., Mayberg, H. S., Schreiber, H., Dehkordi, S. M., Bhattacharyya, S., et al. (2021). Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. Sci. Rep. 11:21011. doi: 10.1038/s41598-021-99845-1
Byndloss, M. X., Olsan, E. E., Rivera-Chávez, F., Tiffany, C. R., Cevallos, S. A., Lokken, K. L., et al. (2017). Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 357, 570–575. doi: 10.1126/science.aam9949
Caruso, R., Warner, N., Inohara, N., and Núñez, G. (2014). NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity 41, 898–908. doi: 10.1016/j.immuni.2014.12.010
Cavallari, J. F., Barra, N. G., Foley, K. P., Lee, A., Duggan, B. M., Henriksbo, B. D., et al. (2020). Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice. Am. J. Physiol. Endocrinol. Metab. 318, E579–E585. doi: 10.1152/ajpendo.00033.2020
Cavallari, J. F., Fullerton, M. D., Duggan, B. M., Foley, K. P., Denou, E., Smith, B. K., et al. (2017). Muramyl dipeptide-based postbiotics mitigate obesity-induced insulin resistance via IRF4. Cell Metab. 25, 1063.e3–1074.e3. doi: 10.1016/j.cmet.2017.03.021
Chan, K. L., Tam, T. H., Boroumand, P., Prescott, D., Costford, S. R., Escalante, N. K., et al. (2017). Circulating NOD1 activators and hematopoietic NOD1 contribute to metabolic inflammation and insulin resistance. Cell Rep. 18, 2415–2426. doi: 10.1016/j.celrep.2017.02.027
Chang, P. V., Hao, L., Offermanns, S., and Medzhitov, R. (2014). The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. U. S. A. 111, 2247–2252. doi: 10.1073/pnas.1322269111
Cox, A. J., West, N. P., and Cripps, A. W. (2015). Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 3, 207–215. doi: 10.1016/s2213-8587(14)70134-2
Craciun, S., and Balskus, E. P. (2012). Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl. Acad. Sci. U. S. A. 109, 21307–21312. doi: 10.1073/pnas.1215689109
Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., and Macfarlane, G. T. (1987). Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221–1227. doi: 10.1136/gut.28.10.1221
Dalile, B., Van Oudenhove, L., Vervliet, B., and Verbeke, K. (2019). The role of short-chain fatty acids in microbiota-gut-brain communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461–478. doi: 10.1038/s41575-019-0157-3
Dalmasso, G., Nguyen, H. T., Charrier-Hisamuddin, L., Yan, Y., Laroui, H., Demoulin, B., et al. (2010). PepT1 mediates transport of the proinflammatory bacterial tripeptide L-Ala-{gamma}-D-Glu-meso-DAP in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G687–G696. doi: 10.1152/ajpgi.00527.2009
Dasgupta, S., Erturk-Hasdemir, D., Ochoa-Reparaz, J., Reinecker, H. C., and Kasper, D. L. (2014). Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe 15, 413–423. doi: 10.1016/j.chom.2014.03.006
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., et al. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563. doi: 10.1038/nature12820
De Angelis, M., Garruti, G., Minervini, F., Bonfrate, L., Portincasa, P., and Gobbetti, M. (2019). The food-gut human axis: the effects of diet on gut microbiota and metabolome. Curr. Med. Chem. 26, 3567–3583. doi: 10.2174/0929867324666170428103848
Do, T., Page, J. E., and Walker, S. (2020). Uncovering the activities, biological roles, and regulation of bacterial cell wall hydrolases and tailoring enzymes. J. Biol. Chem. 295, 3347–3361. doi: 10.1074/jbc.REV119.010155
Dou, L., Jourde-Chiche, N., Faure, V., Cerini, C., Berland, Y., Dignat-George, F., et al. (2007). The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J. Thromb. Haemost. 5, 1302–1308. doi: 10.1111/j.1538-7836.2007.02540.x
Egan, A. J. F., Errington, J., and Vollmer, W. (2020). Regulation of peptidoglycan synthesis and remodelling. Nat. Rev. Microbiol. 18, 446–460. doi: 10.1038/s41579-020-0366-3
Ellouz, F., Adam, A., Ciorbaru, R., and Lederer, E. (1974). Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59, 1317–1325. doi: 10.1016/0006-291x(74)90458-6
Fink, L. N., Costford, S. R., Lee, Y. S., Jensen, T. E., Bilan, P. J., Oberbach, A., et al. (2014). Pro-inflammatory macrophages increase in skeletal muscle of high fat-fed mice and correlate with metabolic risk markers in humans. Obesity 22, 747–757. doi: 10.1002/oby.20615
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450. doi: 10.1038/nature12721
Garrett, W. S., Gordon, J. I., and Glimcher, L. H. (2010). Homeostasis and inflammation in the intestine. Cell 140, 859–870. doi: 10.1016/j.cell.2010.01.023
Gautier, T., David-Le Gall, S., Sweidan, A., Tamanai-Shacoori, Z., Jolivet-Gougeon, A., Loréal, O., et al. (2021). Next-generation probiotics and their metabolites in COVID-19. Microorganisms 9:941. doi: 10.3390/microorganisms9050941
Geuking, M. B., Cahenzli, J., Lawson, M. A., Ng, D. C., Slack, E., Hapfelmeier, S., et al. (2011). Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 34, 794–806. doi: 10.1016/j.immuni.2011.03.021
Geypens, B., Claus, D., Evenepoel, P., Hiele, M., Maes, B., Peeters, M., et al. (1997). Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut 41, 70–76. doi: 10.1136/gut.41.1.70
Girardin, S. E., Boneca, I. G., Carneiro, L. A., Antignac, A., Jéhanno, M., Viala, J., et al. (2003a). Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300, 1584–1587. doi: 10.1126/science.1084677
Girardin, S. E., Boneca, I. G., Viala, J., Chamaillard, M., Labigne, A., Thomas, G., et al. (2003b). Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869–8872. doi: 10.1074/jbc.C200651200
Gonzalez-Santana, A., and Diaz Heijtz, R. (2020). Bacterial peptidoglycans from microbiota in neurodevelopment and behavior. Trends Mol. Med. 26, 729–743. doi: 10.1016/j.molmed.2020.05.003
Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., et al. (2021). Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 373, 1040–1046. doi: 10.1126/science.abc9113
Guo, C., Xie, S., Chi, Z., Zhang, J., Liu, Y., Zhang, L., et al. (2016). Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45, 802–816. doi: 10.1016/j.immuni.2016.09.008
Guryanova, S. V., and Khaitov, R. M. (2021). Strategies for using muramyl peptides – modulators of innate immunity of bacterial origin – in medicine. Front. Immunol. 12:607178. doi: 10.3389/fimmu.2021.607178
Hang, S., Paik, D., Yao, L., Kim, E., Trinath, J., Lu, J., et al. (2019). Bile acid metabolites control TH17 and Treg cell differentiation. Nature 576, 143–148. doi: 10.1038/s41586-019-1785-z
Hooper, L. V., and Macpherson, A. J. (2010). Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 10, 159–169. doi: 10.1038/nri2710
Hu, Y., Song, F., Jiang, H., Nuñez, G., and Smith, D. E. (2018). SLC15A2 and SLC15A4 mediate the transport of bacterially derived Di/Tripeptides to enhance the nucleotide-binding oligomerization domain-dependent immune response in mouse bone marrow-derived macrophages. J. Immunol. 201, 652–662. doi: 10.4049/jimmunol.1800210
Huang, Z., Wang, J., Xu, X., Wang, H., Qiao, Y., Chu, W. C., et al. (2019). Antibody neutralization of microbiota-derived circulating peptidoglycan dampens inflammation and ameliorates autoimmunity. Nat. Microbiol. 4, 766–773. doi: 10.1038/s41564-019-0381-1
Hubbard, T. D., Murray, I. A., Bisson, W. H., Lahoti, T. S., Gowda, K., Amin, S. G., et al. (2015). Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci. Rep. 5:12689. doi: 10.1038/srep12689
Humann, J., Mann, B., Gao, G., Moresco, P., Ramahi, J., Loh, L. N., et al. (2016). Bacterial peptidoglycan traverses the placenta to induce fetal neuroproliferation and aberrant postnatal behavior. Cell Host Microbe 19:901. doi: 10.1016/j.chom.2016.05.017
Ismair, M. G., Vavricka, S. R., Kullak-Ublick, G. A., Fried, M., Mengin-Lecreulx, D., and Girardin, S. E. (2006). hPepT1 selectively transports muramyl dipeptide but not Nod1-activating muramyl peptides. Can. J. Physiol. Pharmacol. 84, 1313–1319. doi: 10.1139/y06-076
Iwamura, C., Bouladoux, N., Belkaid, Y., Sher, A., and Jankovic, D. (2017). Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis. Blood 129, 171–176. doi: 10.1182/blood-2016-06-723742
Jacobson, A., Lam, L., Rajendram, M., Tamburini, F., Honeycutt, J., Pham, T., et al. (2018). A gut commensal-produced metabolite mediates colonization resistance to salmonella infection. Cell Host Microbe 24, 296.e7–307.e7. doi: 10.1016/j.chom.2018.07.002
Jain, U., Lai, C.-W., Xiong, S., Goodwin, V. M., Lu, Q., Muegge, B. D., et al. (2018). Temporal regulation of the bacterial metabolite deoxycholate during colonic repair is critical for crypt regeneration. Cell Host Microbe 24, 353.e5–363.e5. doi: 10.1016/j.chom.2018.07.019
Jia, W., Xie, G., and Jia, W. (2018). Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111–128. doi: 10.1038/nrgastro.2017.119
Joyce, S. A., and Gahan, C. G. (2016). Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu. Rev. Food Sci. Technol. 7, 313–333. doi: 10.1146/annurev-food-041715-033159
Joyce, S. A., Macsharry, J., Casey, P. G., Kinsella, M., Murphy, E. F., Shanahan, F., et al. (2014). Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc. Natl. Acad. Sci. U. S. A. 111, 7421–7426. doi: 10.1073/pnas.1323599111
Kang, J. D., Myers, C. J., Harris, S. C., Kakiyama, G., Lee, I. K., Yun, B. S., et al. (2019). Bile acid 7α-dehydroxylating gut bacteria secrete antibiotics that inhibit Clostridium difficile: role of secondary bile acids. Cell Chem. Biol. 26, 27.e4–34.e4. doi: 10.1016/j.chembiol.2018.10.003
Kannan, N., and Tang, V. W. (2015). Synaptopodin couples epithelial contractility to α-actinin-4-dependent junction maturation. J. Cell Biol. 211, 407–434. doi: 10.1083/jcb.201412003
Kawamoto, K., Horibe, I., and Uchida, K. (1989). Purification and characterization of a new hydrolase for conjugated bile acids, chenodeoxycholyltaurine hydrolase, from Bacteroides vulgatus. J. Biochem. 106, 1049–1053. doi: 10.1093/oxfordjournals.jbchem.a122962
Kim, B., Wang, Y.-C., Hespen, C. W., Espinosa, J., Salje, J., Rangan, K. J., et al. (2019). Enterococcus faecium secreted antigen A generates muropeptides to enhance host immunity and limit bacterial pathogenesis. elife 8:e45343. doi: 10.7554/eLife.45343
Kundu, P., Lee, H. U., Garcia-Perez, I., Tay, E. X. Y., Kim, H., Faylon, L. E., et al. (2019). Neurogenesis and prolongevity signaling in young germ-free mice transplanted with the gut microbiota of old mice. Sci. Transl. Med. 11:eaau4760. doi: 10.1126/scitranslmed.aau4760
Laman, J. D., A ‘t Hart, B., Power, C., and Dziarski, R. (2020). Bacterial peptidoglycan as a driver of chronic brain inflammation. Trends Mol. Med. 26, 670–682. doi: 10.1016/j.molmed.2019.11.006
Lavelle, A., and Sokol, H. (2020). Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 17, 223–237. doi: 10.1038/s41575-019-0258-z
Ley, R. E., Peterson, D. A., and Gordon, J. I. (2006). Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837–848. doi: 10.1016/j.cell.2006.02.017
Li, W., Hang, S., Fang, Y., Bae, S., Zhang, Y., Zhang, M., et al. (2021). A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1. Cell Host Microbe 29, 1366.e9–1377.e9. doi: 10.1016/j.chom.2021.07.013
Liu, Y., Yang, K., Jia, Y., Shi, J., Tong, Z., Fang, D., et al. (2021). Gut microbiome alterations in high-fat-diet-fed mice are associated with antibiotic tolerance. Nat. Microbiol. 6, 874–884. doi: 10.1038/s41564-021-00912-0
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., et al. (2018). Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360:eaan5931. doi: 10.1126/science.aan5931
Macia, L., Tan, J., Vieira, A. T., Leach, K., Stanley, D., Luong, S., et al. (2015). Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6:6734. doi: 10.1038/ncomms7734
Maloy, K. J., and Powrie, F. (2011). Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298–306. doi: 10.1038/nature10208
Martin, C. R., Osadchiy, V., Kalani, A., and Mayer, E. A. (2018). The brain-gut-microbiome axis. Cell. Mol. Gastroenterol. Hepatol. 6, 133–148. doi: 10.1016/j.jcmgh.2018.04.003
Mazmanian, S. K., Liu, C. H., Tzianabos, A. O., and Kasper, D. L. (2005). An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107–118. doi: 10.1016/j.cell.2005.05.007
Mohseni, A. H., Taghinezhad-S, S., and Fu, X. (2020). Gut microbiota-derived metabolites and colorectal cancer: new insights and updates. Microb. Pathog. 149:104569. doi: 10.1016/j.micpath.2020.104569
Morinaga, H., Mayoral, R., Heinrichsdorff, J., Osborn, O., Franck, N., Hah, N., et al. (2015). Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice. Diabetes 64, 1120–1130. doi: 10.2337/db14-1238
Mun, G. I., Park, S., Kremerskothen, J., and Boo, Y. C. (2014). Expression of synaptopodin in endothelial cells exposed to laminar shear stress and its role in endothelial wound healing. FEBS Lett. 588, 1024–1030. doi: 10.1016/j.febslet.2014.02.012
Nakamura, N., Lill, J. R., Phung, Q., Jiang, Z., Bakalarski, C., De Mazière, A., et al. (2014). Endosomes are specialized platforms for bacterial sensing and NOD2 signalling. Nature 509, 240–244. doi: 10.1038/nature13133
Natividad, J. M., Agus, A., Planchais, J., Lamas, B., Jarry, A. C., Martin, R., et al. (2018). Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab. 28, 737.e4–749.e4. doi: 10.1016/j.cmet.2018.07.001
Neff, C. P., Rhodes, M. E., Arnolds, K. L., Collins, C. B., Donnelly, J., Nusbacher, N., et al. (2016). Diverse intestinal bacteria contain putative zwitterionic capsular polysaccharides with anti-inflammatory properties. Cell Host Microbe 20, 535–547. doi: 10.1016/j.chom.2016.09.002
Nguyen, T. T., Ung, T. T., Kim, N. H., and Jung, Y. D. (2018). Role of bile acids in colon carcinogenesis. World J. Clin. Cases 6, 577–588. doi: 10.12998/wjcc.v6.i13.577
Ni, J., Wu, G. D., Albenberg, L., and Tomov, V. T. (2017). Gut microbiota and IBD: causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 14, 573–584. doi: 10.1038/nrgastro.2017.88
Nigro, G., Rossi, R., Commere, P.-H., Jay, P., and Sansonetti, P. J. (2014). The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration. Cell Host Microbe 15, 792–798. doi: 10.1016/j.chom.2014.05.003
Organ, C. L., Li, Z., Sharp, T. E. 3rd, Polhemus, D. J., Gupta, N., Goodchild, T. T., et al. (2020). Nonlethal inhibition of gut microbial trimethylamine N-oxide production improves cardiac function and remodeling in a murine model of heart failure. J. Am. Heart Assoc. 9:e016223. doi: 10.1161/jaha.119.016223
Paik, D., Monahan, A., Caffrey, D. R., Elling, R., Goldman, W. E., and Silverman, N. (2017). SLC46 family transporters facilitate cytosolic innate immune recognition of monomeric peptidoglycans. J. Immunol. 199, 263–270. doi: 10.4049/jimmunol.1600409
Pedicord, V. A., Lockhart, A. A. K., Rangan, K. J., Craig, J. W., Loschko, J., Rogoz, A., et al. (2016). Exploiting a host-commensal interaction to promote intestinal barrier function and enteric pathogen tolerance. Sci. Immunol. 1:eaai7732. doi: 10.1126/sciimmunol.aai7732
Peterson, L. W., and Artis, D. (2014). Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14, 141–153. doi: 10.1038/nri3608
Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65. doi: 10.1038/nature08821
Quinn, R. A., Melnik, A. V., Vrbanac, A., Fu, T., Patras, K. A., Christy, M. P., et al. (2020). Global chemical effects of the microbiome include new bile-acid conjugations. Nature 579, 123–129. doi: 10.1038/s41586-020-2047-9
Ramakrishna, C., Kujawski, M., Chu, H., Li, L., Mazmanian, S. K., and Cantin, E. M. (2019). Bacteroides fragilis polysaccharide A induces IL-10 secreting B and T cells that prevent viral encephalitis. Nat. Commun. 10:2153. doi: 10.1038/s41467-019-09884-6
Rangan, K. J., Pedicord, V. A., Wang, Y. C., Kim, B., Lu, Y., Shaham, S., et al. (2016). A secreted bacterial peptidoglycan hydrolase enhances tolerance to enteric pathogens. Science 353, 1434–1437. doi: 10.1126/science.aaf3552
Ridlon, J. M., Kang, D.-J., and Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241–259. doi: 10.1194/jlr.R500013-JLR200
Rivera-Chávez, F., Zhang, L. F., Faber, F., Lopez, C. A., Byndloss, M. X., Olsan, E. E., et al. (2016). Depletion of butyrate-producing clostridia from the gut microbiota drives an aerobic luminal expansion of salmonella. Cell Host Microbe 19, 443–454. doi: 10.1016/j.chom.2016.03.004
Roager, H. M., and Licht, T. R. (2018). Microbial tryptophan catabolites in health and disease. Nat. Commun. 9:3294. doi: 10.1038/s41467-018-05470-4
Roberts, A. B., Gu, X., Buffa, J. A., Hurd, A. G., Wang, Z., Zhu, W., et al. (2018). Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat. Med. 24, 1407–1417. doi: 10.1038/s41591-018-0128-1
Rothhammer, V., and Quintana, F. J. (2019). The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat. Rev. Immunol. 19, 184–197. doi: 10.1038/s41577-019-0125-8
Round, J. L., Lee, S. M., Li, J., Tran, G., Jabri, B., Chatila, T. A., et al. (2011). The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332, 974–977. doi: 10.1126/science.1206095
Russell, D. W. (2003). The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137–174. doi: 10.1146/annurev.biochem.72.121801.161712
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167, 1469.e12–1480.e12. doi: 10.1016/j.cell.2016.11.018
Schertzer, J. D., and Klip, A. (2011). Give a NOD to insulin resistance. Am. J. Physiol. Endocrinol. Metab. 301, E585–E586. doi: 10.1152/ajpendo.00362.2011
Schertzer, J. D., Tamrakar, A. K., Klip, A., Magalhaes, J. G., Pereira, S., Bilan, P. J., et al. (2011). NOD1 activators link innate immunity to insulin resistance. Diabetes 60, 2206–2215. doi: 10.2337/db11-0004
Schönfeld, P., and Wojtczak, L. (2016). Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J. Lipid Res. 57, 943–954. doi: 10.1194/jlr.R067629
Schrijver, I. A., Van Meurs, M., Melief, M. J., Wim Ang, C., Buljevac, D., Ravid, R., et al. (2001). Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis. Brain 124, 1544–1554. doi: 10.1093/brain/124.8.1544
Schroeder, J. C., Dinatale, B. C., Murray, I. A., Flaveny, C. A., Liu, Q., Laurenzana, E. M., et al. (2010). The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 49, 393–400. doi: 10.1021/bi901786x
Schulthess, J., Pandey, S., Capitani, M., Rue-Albrecht, K. C., Arnold, I., Franchini, F., et al. (2019). The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity 50, 432.e437–445.e437. doi: 10.1016/j.immuni.2018.12.018
Sen, Z., and Karnovsky, M. L. (1984). Qualitative detection of muramic acid in normal mammalian tissues. Infect. Immun. 43, 937–941. doi: 10.1128/iai.43.3.937-941.1984
Shaw, P. J., Barr, M. J., Lukens, J. R., Mcgargill, M. A., Chi, H., Mak, T. W., et al. (2011). Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity 34, 75–84. doi: 10.1016/j.immuni.2010.12.015
Silva, Y. P., Bernardi, A., and Frozza, R. L. (2020). The role of short-chain fatty acids From gut microbiota in gut-brain communication. Front. Endocrinol. 11:25. doi: 10.3389/fendo.2020.00025
Simó, C., and García-Cañas, V. (2020). Dietary bioactive ingredients to modulate the gut microbiota-derived metabolite TMAO. New opportunities for functional food development. Food Funct. 11, 6745–6776. doi: 10.1039/D0FO01237H
Singh, R. K., Chang, H.-W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., et al. (2017). Influence of diet on the gut microbiome and implications for human health. J. Transl. Med. 15:73. doi: 10.1186/s12967-017-1175-y
Sinha, S. R., Haileselassie, Y., Nguyen, L. P., Tropini, C., Wang, M., Becker, L. S., et al. (2020). Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 27, 659.e5–670.e5. doi: 10.1016/j.chom.2020.01.021
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., et al. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573. doi: 10.1126/science.1241165
Song, X., Sun, X., Oh, S. F., Wu, M., Zhang, Y., Zheng, W., et al. (2020). Microbial bile acid metabolites modulate gut RORγ + regulatory T cell homeostasis. Nature 577, 410–415. doi: 10.1038/s41586-019-1865-0
Stein, J., Zores, M., and Schröder, O. (2000). Short-chain fatty acid (SCFA) uptake into Caco-2 cells by a pH-dependent and carrier mediated transport mechanism. Eur. J. Nutr. 39, 121–125. doi: 10.1007/s003940070028
Sun, M., Wu, W., Chen, L., Yang, W., Huang, X., Ma, C., et al. (2018). Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. Nat. Commun. 9:3555. doi: 10.1038/s41467-018-05901-2
Surana, N. K., and Kasper, D. L. (2012). The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA. Immunol. Rev. 245, 13–26. doi: 10.1111/j.1600-065X.2011.01075.x
Tamrakar, A. K., Schertzer, J. D., Chiu, T. T., Foley, K. P., Bilan, P. J., Philpott, D. J., et al. (2010). NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. Endocrinology 151, 5624–5637. doi: 10.1210/en.2010-0437
Tan, C. T., Xu, X., Qiao, Y., and Wang, Y. (2021). A peptidoglycan storm caused by β-lactam antibiotic’s action on host microbiota drives Candida albicans infection. Nat. Commun. 12:2560. doi: 10.1038/s41467-021-22845-2
Varela, R. B., Valvassori, S. S., Lopes-Borges, J., Mariot, E., Dal-Pont, G. C., Amboni, R. T., et al. (2014). Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats. J. Psychiatr. Res. 61, 114–121. doi: 10.1016/j.jpsychires.2014.11.003
Varol, C., Zigmond, E., and Jung, S. (2010). Securing the immune tightrope: mononuclear phagocytes in the intestinal lamina propria. Nat. Rev. Immunol. 10, 415–426. doi: 10.1038/nri2778
Vavricka, S. R., Musch, M. W., Chang, J. E., Nakagawa, Y., Phanvijhitsiri, K., Waypa, T. S., et al. (2004). hPepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 127, 1401–1409. doi: 10.1053/j.gastro.2004.07.024
Vernay, T., Cannie, I., Gaboriau, F., Gall, S. D., Tamanai-Shacoori, Z., Burel, A., et al. (2020). Bacteroides fragilis prevents salmonella Heidelberg translocation in co-culture model mimicking intestinal epithelium. Benefic. Microbes 11, 391–401. doi: 10.3920/bm2020.0004
Vijay, N., and Morris, M. E. (2014). Role of monocarboxylate transporters in drug delivery to the brain. Curr. Pharm. Des. 20, 1487–1498. doi: 10.2174/13816128113199990462
Vollmer, W., Blanot, D., and De Pedro, M. A. (2008). Peptidoglycan structure and architecture. FEMS Microbiol. Rev. 32, 149–167. doi: 10.1111/j.1574-6976.2007.00094.x
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., Dugar, B., et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63. doi: 10.1038/nature09922
Wang, R. X., Lee, J. S., Campbell, E. L., and Colgan, S. P. (2020). Microbiota-derived butyrate dynamically regulates intestinal homeostasis through regulation of actin-associated protein synaptopodin. Proc. Natl. Acad. Sci. U. S. A. 117, 11648–11657. doi: 10.1073/pnas.1917597117
Wang, Q., Lu, Y., Yuan, M., Darling, I. M., Repasky, E. A., and Morris, M. E. (2006). Characterization of monocarboxylate transport in human kidney HK-2 cells. Mol. Pharm. 3, 675–685. doi: 10.1021/mp060037b
Wang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., et al. (2015). Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585–1595. doi: 10.1016/j.cell.2015.11.055
Weiser, J. N., Clarke, T. B., Davis, K. M., Lysenko, E. S., Zhou, A. Y., and Yu, Y. (2010). Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 16, 228–231. doi: 10.1038/nm.2087
Weiss, G. A., and Hennet, T. (2017). Mechanisms and consequences of intestinal dysbiosis. Cell. Mol. Life Sci. 74, 2959–2977. doi: 10.1007/s00018-017-2509-x
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., et al. (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. U. S. A. 106, 3698–3703. doi: 10.1073/pnas.0812874106
Witkowski, M., Weeks, T. L., and Hazen, S. L. (2020). Gut microbiota and cardiovascular disease. Circ. Res. 127, 553–570. doi: 10.1161/circresaha.120.316242
Wlodarska, M., Luo, C., Kolde, R., D’hennezel, E., Annand, J. W., Heim, C. E., et al. (2017). Indoleacrylic acid produced by commensal Peptostreptococcus species suppresses inflammation. Cell Host Microbe 22, 25.e6–37.e6. doi: 10.1016/j.chom.2017.06.007
Wolf, A. J., and Underhill, D. M. (2018). Peptidoglycan recognition by the innate immune system. Nat. Rev. Immunol. 18, 243–254. doi: 10.1038/nri.2017.136
Wu, I. W., Hsu, K. H., Lee, C. C., Sun, C. Y., Hsu, H. J., Tsai, C. J., et al. (2011). P-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol. Dial. Transplant. 26, 938–947. doi: 10.1093/ndt/gfq580
Yamamura, R., Nakamura, K., Kitada, N., Aizawa, T., Shimizu, Y., Nakamura, K., et al. (2020). Associations of gut microbiota, dietary intake, and serum short-chain fatty acids with fecal short-chain fatty acids. Biosci. Microbiota Food Health 39, 11–17. doi: 10.12938/bmfh.19-010
Yang, S., Li, X., Yang, F., Zhao, R., Pan, X., Liang, J., et al. (2019). Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front. Pharmacol. 10:1360. doi: 10.3389/fphar.2019.01360
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., et al. (2015). Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 163:258. doi: 10.1016/j.cell.2015.09.017
Yao, L., Seaton, S. C., Ndousse-Fetter, S., Adhikari, A. A., Dibenedetto, N., Mina, A. I., et al. (2018). A selective gut bacterial bile salt hydrolase alters host metabolism. eLife 7:e37182. doi: 10.7554/eLife.37182
Zaki, M. H., Boyd, K. L., Vogel, P., Kastan, M. B., Lamkanfi, M., and Kanneganti, T. D. (2010). The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32, 379–391. doi: 10.1016/j.immuni.2010.03.003
Zhang, Q., Pan, Y., Zeng, B., Zheng, X., Wang, H., Shen, X., et al. (2019). Intestinal lysozyme liberates Nod1 ligands from microbes to direct insulin trafficking in pancreatic beta cells. Cell Res. 29, 516–532. doi: 10.1038/s41422-019-0190-3
Zhao, L., Hu, P., Zhou, Y., Purohit, J., and Hwang, D. (2011). NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 301, E587–E598. doi: 10.1152/ajpendo.00709.2010
Zhu, Y., Jameson, E., Crosatti, M., Schäfer, H., Rajakumar, K., Bugg, T. D. H., et al. (2014). Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. U. S. A. 111, 4268–4273. doi: 10.1073/pnas.1316569111
Keywords: gut microbiota-derived metabolites, short-chain fatty acids, bile acids, peptidoglycan fragments, adaptive and innate immunity, host homeostasis
Citation: Li C, Liang Y and Qiao Y (2022) Messengers From the Gut: Gut Microbiota-Derived Metabolites on Host Regulation. Front. Microbiol. 13:863407. doi: 10.3389/fmicb.2022.863407
Edited by:
Luigina Romani, University of Perugia, ItalyReviewed by:
Sarah O’Flaherty, North Carolina State University, United StatesLatifa Bousarghin, University of Rennes 1, France
Copyright © 2022 Li, Liang and Qiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuan Qiao, yuan.qiao@ntu.edu.sg